{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:17:32Z","timestamp":1787797052314,"version":"build-2784847793"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Disease reactivation following cessation of sphingosine 1-phosphate receptor modulators (S1PRM) occurs in\u2009~\u200910% of multiple sclerosis (MS) patients. The biological factors underlying this phenomenon remain incompletely understood, including the potential contribution of sex-specific differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review on published literature and adverse event registries (FAERS, EudraVigilance), as of January 2024, focusing exclusively on fingolimod (FTY) withdrawal in individuals with MS. Disease severity after FTY withdrawal was assessed in the experimental autoimmune encephalomyelitis (EAE) mouse model, using untreated EAE mice as controls. S1P receptor expression was analyzed by immunofluorescence in spinal cord tissue from EAE mice and in brain biopsies from MS patients with disease reactivation after FTY withdrawal and MS controls (no prior FTY or S1PRM treatment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analysis of eight studies (n\u2009=\u20092579) demonstrated an association between female sex and disease reactivation after FTY cessation (odds ratios: 1.09\u20137.20), corroborated by pharmacovigilance data (FAERS: OR\u2009=\u20092.00,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001; EudraVigilance: OR\u2009=\u20092.42,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Female EAE mice exhibited greater post-FTY treatment disease severity (2.5-fold increase,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) with increased S1PR1 expression on CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Human brain biopsies showed elevated S1PR1 expression on CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells in active demyelinating lesions during disease reactivation compared to inactive demyelinated lesions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Across clinical, experimental, and neuropathological analyses, female sex was associated with more pronounced disease activity following FTY withdrawal. Increased S1PR1 expression in T cells represents a potential cellular correlate of this sex-associated vulnerability and warrants further mechanistic investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40478-026-02343-6","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:33:17Z","timestamp":1781728397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher disease reactivation risk in women after fingolimod withdrawal"],"prefix":"10.1186","volume":"14","author":[{"given":"Marine","family":"Massy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane","family":"Kutllovci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Frahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Fneish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ellenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helly","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Leichtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"L\u00fchder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Pistor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"18","key":"2343_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12182291","volume":"12","author":"M Bagnoud","year":"2023","unstructured":"Bagnoud M, Remlinger J, Massy M, Lodygin D, Salmen A, Chan A, L\u00fchder F, Hoepner R (2023) In vivo and in vitro evidence for an interplay between the glucocorticoid receptor and the vitamin D receptor signaling. Cells 12(18):2291. https:\/\/doi.org\/10.3390\/cells12182291","journal-title":"Cells"},{"key":"2343_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.msard.2017.12.003","volume":"20","author":"M Baharnoori","year":"2018","unstructured":"Baharnoori M, Gonzalez CT, Chua A, Diaz-Cruz C, Healy BC, Stankiewicz J, Weiner HL, Chitnis T (2018) Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord 20:51\u201357. https:\/\/doi.org\/10.1016\/j.msard.2017.12.003","journal-title":"Mult Scler Relat Disord"},{"key":"2343_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103329","volume":"57","author":"A Barboza","year":"2022","unstructured":"Barboza A, Gait\u00e1n MI, Alonso R, Ysrraelit MC, Luetic G, Liwacki S, Patrucco L, Halfon MJ, Burgos M, Mainella C, Pierdabuena R, Recchia L, Steinberg J, Tkachuk VA, Zanga G, Carra A, Chertcoff A, Fernandez Liguori N, Lazaro L, Menichini ML, Miguez J, Orzuza G, Palavecino A, Pappolla A, Pigretti S, Pita C, Ruiz E, Silva B, Zentil G (2022) Rebound activity after fingolimod cessation: a case\u2014control study. Mult Scler Relat Disord 57:103329. https:\/\/doi.org\/10.1016\/j.msard.2021.103329","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2343_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","volume":"8","author":"B Barry","year":"2019","unstructured":"Barry B, Erwin AA, Stevens J, Tornatore C (2019) Fingolimod rebound: a review of the clinical experience and management considerations. Neurol Ther 8(2):241\u2013250. https:\/\/doi.org\/10.1007\/s40120-019-00160-9","journal-title":"Neurol Ther"},{"key":"2343_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13072-024-00525-x","volume":"17","author":"S Bhattacharya","year":"2024","unstructured":"Bhattacharya S, Sadhukhan D, Saraswathy R (2024) Role of sex in immune response and epigenetic mechanisms. Epigenetics Chromatin 17:1\u201313. https:\/\/doi.org\/10.1186\/s13072-024-00525-x","journal-title":"Epigenetics Chromatin"},{"issue":"8","key":"2343_CR6","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1194\/jlr.r046300","volume":"55","author":"VA Blaho","year":"2014","unstructured":"Blaho VA, Hla T (2014) An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 55(8):1596\u20131608. https:\/\/doi.org\/10.1194\/jlr.r046300","journal-title":"J Lipid Res"},{"key":"2343_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883\u2013897","journal-title":"Nat Rev Drug Discov"},{"key":"2343_CR8","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1074\/jbc.c200176200","volume":"277","author":"V Brinkmann","year":"2002","unstructured":"Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453\u201321457. https:\/\/doi.org\/10.1074\/jbc.c200176200","journal-title":"J Biol Chem"},{"key":"2343_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/ana.410380514","volume":"38","author":"W Br\u00fcck","year":"1996","unstructured":"Br\u00fcck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Lassmann H (1996) Monocyte\/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38:788\u2013796","journal-title":"Ann Neurol"},{"key":"2343_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nbd.2023.106113","volume":"181","author":"JF Catal\u00e0-Senent","year":"2023","unstructured":"Catal\u00e0-Senent JF, Andreu Z, Jos\u00e9 Roig F, Hidalgo MR, Yanguas-Cas\u00e1s N, Neva-Alejo A, L\u00f3pez-Cerd\u00e1n A, Soler-S\u00e1ez I, de la Iglesia-Vay\u00e1 M, Garc\u00eda-Garc\u00eda F (2023) A deep transcriptome meta-analysis reveals sex-based molecular differences in Multiple Sclerosis. Neurobiol Dis 181:106\u2013113","journal-title":"Neurobiol Dis"},{"key":"2343_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","volume":"50","author":"L Cavone","year":"2015","unstructured":"Cavone L, Felici R, Lapucci A, Buonvicino D, Pratesi S, Muzzi M, Hakiki B, Maggi L, Peruzzi B, Caporale R, Annunziato F, Amato MP, Chiarugi A (2015) Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. Brain Behav Immun 50:78\u201386. https:\/\/doi.org\/10.1016\/j.bbi.2015.06.019","journal-title":"Brain Behav Immun"},{"key":"2343_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221150312","author":"N Cerd\u00e1-Fuertes","year":"2023","unstructured":"Cerd\u00e1-Fuertes N, Nagy S, Schaedelin S, Sinnecker T, Ruberte E, Papadopoulou A, W\u00fcrfel J, Kuhle J, Yaldizli \u00d6, Kappos L, Derfuss T, D\u00e9card BF (2023) Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864221150312","journal-title":"Ther Adv Neurol Disord"},{"key":"2343_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clim.2013.03.014","volume":"149","author":"T Chitnis","year":"2013","unstructured":"Chitnis T (2013) Role of puberty in multiple sclerosis risk and course. Clin Immunol 149:192\u2013200. https:\/\/doi.org\/10.1016\/j.clim.2013.03.014","journal-title":"Clin Immunol"},{"key":"2343_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/nejmoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral Fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415. https:\/\/doi.org\/10.1056\/nejmoa0907839","journal-title":"N Engl J Med"},{"key":"2343_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 18:1021\u20131033. https:\/\/doi.org\/10.1016\/S1474-4422(19)30238-8","journal-title":"Lancet Neurol"},{"key":"2343_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdov\u00e1 E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 18:1009\u20131020. https:\/\/doi.org\/10.1016\/S1474-4422(19)30239-X","journal-title":"Lancet Neurol"},{"key":"2343_CR17","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502\u20131517. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7","journal-title":"Lancet"},{"key":"2343_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.immunol.23.021704.115628","volume":"23","author":"JG Cyster","year":"2005","unstructured":"Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127\u2013159","journal-title":"Annu Rev Immunol"},{"key":"2343_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12883-021-02058-2","volume":"21","author":"S Delgado","year":"2021","unstructured":"Delgado S, Hernandez J, Tornes L, Rammohan K (2021) Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series. BMC Neurol 21:2\u20136. https:\/\/doi.org\/10.1186\/s12883-021-02058-2","journal-title":"BMC Neurol"},{"key":"2343_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1212\/WNL.63.12_suppl_6.S3","volume":"15","author":"C Dendrou","year":"2015","unstructured":"Dendrou C, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545\u2013558. https:\/\/doi.org\/10.1212\/WNL.63.12_suppl_6.S3","journal-title":"Nat Rev Immunol"},{"key":"2343_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","volume":"11","author":"V Devonshire","year":"2012","unstructured":"Devonshire V, Havrdova E, Radue EW, O\u2019Connor P, Zhang-Auberson L, Agoropoulou C et al (2012) Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 11:420\u2013428. https:\/\/doi.org\/10.1016\/S1474-4422(12)70056-X","journal-title":"Lancet Neurol"},{"key":"2343_CR22","unstructured":"European Medicines Agency EudraVigilance (02023) European database of suspected adverse drug reactions. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance. Accessed 12 Jan 2023"},{"key":"2343_CR23","unstructured":"European Medicines Agency ADR Reports: Online access to suspected side-effect reports (2023) https:\/\/www.adrreports.eu\/en\/index.html. Accessed 12 Jan 2023"},{"key":"2343_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/cns.12992","volume":"24","author":"ME Evangelopoulos","year":"2018","unstructured":"Evangelopoulos ME, Miclea A, Schrewe L, Briner M, Salmen A, Engelhardt B, Huwiler A, Chan A, Hoepner R (2018) Frequency and clinical characteristics of multiple sclerosis rebounds after withdrawal of fingolimod. CNS Neurosci Ther 24:984\u2013986. https:\/\/doi.org\/10.1111\/cns.12992","journal-title":"CNS Neurosci Ther"},{"key":"2343_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1756285615594575","volume":"8","author":"S Faissner","year":"2015","unstructured":"Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G (2015) Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 8:233\u2013238","journal-title":"Ther Adv Neurol Disord"},{"key":"2343_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple sclerosis. Nat Rev Dis Primers 4:1\u201327. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Primers"},{"key":"2343_CR27","doi-asserted-by":"publisher","first-page":"eado0398","DOI":"10.1126\/sciimmunol.ado0398","volume":"9","author":"KS Forsyth","year":"2024","unstructured":"Forsyth KS, Toothacre NE, Jiwrajka N, Driscoll AM, Shallberg LA, Cunningham-Rundles C, Barmettler S, Farmer J, Verbsky J, Routes J, Beiting DP, Romberg N, May MJ, Anguera MC (2024) Maintenance of X chromosome inactivation after T cell activation requires NF-\u03baB signaling. Sci Immunol 9:eado0398. https:\/\/doi.org\/10.1126\/sciimmunol.ado0398","journal-title":"Sci Immunol"},{"key":"2343_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40120-021-00320-w","volume":"11","author":"N Frahm","year":"2022","unstructured":"Frahm N, Fneish F, Ellenberger D, Flachenecker P, Paul F, Warnke C, Kleinschnitz C, Parciak T, Krefting D, Hellwig K, Haas J, Rommer PS, Stahmann A, Zettl UK (2022) Therapy switches in fingolimod-treated patients with multiple sclerosis: long-term experience from the German MS registry. Neurology and Therapy 11:319\u2013336. https:\/\/doi.org\/10.1007\/s40120-021-00320-w","journal-title":"Neurology and Therapy"},{"key":"2343_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/jnnp-2022-329607","volume":"93","author":"E Framke","year":"2022","unstructured":"Framke E, Pontieri L, Bramow S, Sellebjerg F, Magyari M (2022) Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark. J Neurol Neurosurg Psychiatry 93:1317\u20131321. https:\/\/doi.org\/10.1136\/jnnp-2022-329607","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2343_CR30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1352458517713147","volume":"23","author":"M Ghadiri","year":"2017","unstructured":"Ghadiri M, Fitz-Gerald L, Rezk A, Li R, Nyirenda M, Haegert D, Giacomini PS, Bar-Or A, Antel J (2017) Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Mult Scler 23:1225\u20131232. https:\/\/doi.org\/10.1177\/1352458517713147","journal-title":"Mult Scler"},{"key":"2343_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1177\/1352458518763095","volume":"24","author":"MT Giordana","year":"2018","unstructured":"Giordana MT, Cavalla P, Uccelli A, Laroni A, Bandini F, Vercellino M, Mancardi G (2018) Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. Mult Scler 24:1133\u20131137. https:\/\/doi.org\/10.1177\/1352458518763095","journal-title":"Mult Scler"},{"key":"2343_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-065X.2012.01134.x","volume":"248","author":"PA Gourraud","year":"2012","unstructured":"Gourraud PA, Harbo HF, Hauser SL, Baranzini SE (2012) The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 248:87\u2013103. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01134.x","journal-title":"Immunol Rev"},{"key":"2343_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS (2016) Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73:790\u2013794. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0826","journal-title":"JAMA Neurol"},{"key":"2343_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.yfrne.2018.07.001","volume":"50","author":"MK Houtchens","year":"2018","unstructured":"Houtchens MK, Bove R (2018) A case for gender-based approach to multiple sclerosis therapeutics. Front Neuroendocrinol 50:123\u2013134. https:\/\/doi.org\/10.1016\/j.yfrne.2018.07.001","journal-title":"Front Neuroendocrinol"},{"key":"2343_CR35","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1172\/JCI126250","volume":"129","author":"Y Itoh","year":"2019","unstructured":"Itoh Y, Golden LC, Itoh N, Matsukawa MA, Ren E, Tse V, Arnold AP, Voskuhl RR (2019) The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity. J Clin Invest 129:3852\u20133863. https:\/\/doi.org\/10.1172\/JCI126250","journal-title":"J Clin Invest"},{"key":"2343_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq3401","author":"Y Itoh","year":"2025","unstructured":"Itoh Y, Itoh N, Wendin S, Higgins N, Voskuhl RR (2025) Deletion of the X-chromosomal gene Kdm6a in microglia of female mice ameliorates neuroinflammation and restores translatome profiles. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.adq3401","journal-title":"Sci Transl Med"},{"key":"2343_CR37","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/nejmoa052643","volume":"355","author":"L Kappos","year":"2006","unstructured":"Kappos L, Antel J, Comi G, Montalban X, O\u2019Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. N Engl J Med 355:1124\u20131140. https:\/\/doi.org\/10.1056\/nejmoa052643","journal-title":"N Engl J Med"},{"key":"2343_CR38","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstr\u00f6m E, Dahlke F, Achiron A, Achtnichts L, Agan K, Akman-Demir G, Allen AB, Antel JP, Antiguedad AR, Apperson M, Applebee AM, Ayuso GI, Baba M, Bajenaru O, Balasa R, Balci BP, Barnett M, Bass A, Becker VU, Bejinariu M, Bergh FT, Bergmann A, Bernitsas E, Berthele A, Bhan V, Bischof F, Bjork RJ, Blevins G, Boehringer M, Boerner T, Bonek R, Bowen JD, Bowling A, Boyko AN, Boz C, Bracknies V, Braune S, Brescia Morra V, Brochet B, Brola W, Brownstone PK, Brozman M, Brunet D, Buraga I, Burnett M, Buttmann M, Butzkueven H, Cahill J, Calkwood JC, Camu W, Cascione M, Castelnovo G, Centonze D, Cerqueira J, Chan A, Cimprichova A, Cohan S, Comi G, Conway J, Cooper JA, Corboy J, Correale J, Costell B, Cottrell DA, Coyle PK, Craner M, Cui L, Cunha L, Czlonkowska A, da Silva AM, de Sa J, de Seze J, Debouverie M, Debruyne J, Decoo D, Defer G, Derfuss T, Deri NH, Dihenia B, Dioszeghy P, Donath V, Dubois B, Duddy M, Duquette P, Edan G, Efendi H, Elias S, Emrich PJ, Estruch BC, Evdoshenko EP, Faiss J, Fedyanin AS, Feneberg W, Fermont J, Fernandez OF, Ferrer FC, Fink K, Ford H, Ford C, Francia A, Freedman M, Frishberg B, Galgani S, Garmany GP, Gehring K, Gitt J, Gobbi C, Goldstick LP, Gonzalez RA, Grandmaison F, Grigoriadis N, Grigorova O, Grimaldi LME, Gross J, Gross-Paju K, Gudesblatt M, Guillaume D, Haas J, Hancinova V, Hancu A, Hardiman O, Harmjanz A, Heidenreich FR, Hengstman GJD, Herbert J, Herring M, Hodgkinson S, Hoffmann OM, Hofmann WE, Honeycutt WD, Hua LH, Huang D, Huang Y, Huang DR, Hupperts R, Imre P, Jacobs AK, Jakab G, Jasinska E, Kaida K, Kalnina J, Kaprelyan A, Karelis G, Karussis D, Katz A, Khabirov FA, Khatri B, Kimura T, Kister I, Kizlaitiene R, Klimova E, Koehler J, Komatineni A, Kornhuber A, Kovacs K, Koves A, Kozubski W, Krastev G, Krupp LB, Kurca E, Lassek C, Laureys G, Lee L, Lensch E, Leutmezer F, Li H, Linker RA, Linnebank M, Liskova P, Llanera C, Lu J, Lutterotti A, Lycke J, Macdonell R, Maciejowski M, Maeurer M, Magzhanov RV, Maida EM, Malciene L, Mao-Draayer Y, Marfia GA, Markowitz C, Mastorodimos V, Matyas K, Meca-Lallana J, Merino JAG, Mihetiu IG, Milanov I, Miller AE, Millers A, Mirabella M, Mizuno M, Montalban X, Montoya L, Mori M, Mueller S, Nakahara J, Nakatsuji Y, Newsome S, Nicholas R, Nielsen AS, Nikfekr E, Nocentini U, Nohara C, Nomura K, Odinak MM, Olsson T, van Oosten BW, Oreja-Guevara C, Oschmann P, Overell J, Pachner A, Panczel G, Pandolfo M, Papeix C, Patrucco L, Pelletier J, Piedrabuena R, Pless M, Polzer U, Pozsegovits K, Rastenyte D, Rauer S, Reifschneider G, Rey R, Rizvi SA, Robertson D, Rodriguez JM, Rog D, Roshanisefat H, Rowe V, Rozsa C, Rubin S, Rusek S, Sacc\u00e0 F, Saida T, Salgado AV, Sanchez VEF, Sanders K, Satori M, Sazonov DV, Scarpini EA, Schlegel E, Schluep M, Schmidt S, Scholz E, Schrijver HM, Schwab M, Schwartz R, Scott J, Selmaj K, Shafer S, Sharrack B, Shchukin IA, Shimizu Y, Shotekov P, Siever A, Sigel KO, Silliman S, Simo M, Simu M, Sinay V, Siquier AE, Siva A, Skoda O, Solomon A, Stangel M, Stefoski D, Steingo B, Stolyarov ID, Stourac P, Strassburger-Krogias K, Strauss E, Stuve O, Tarnev I, Tavernarakis A, Tello CR, Terzi M, Ticha V, Ticmeanu M, Tiel-Wilck K, Toomsoo T, Tubridy N, Tullman MJ, Tumani H, Turcani P, Turner B, Uccelli A, Urtaza FJO, Vachova M, Valikovics A, Walter S, Van Wijmeersch B, Vanopdenbosch L, Weber JR, Weiss S, Weissert R, Vermersch P, West T, Wiendl H, Wiertlewski S, Wildemann B, Willekens B, Visser LH, Vorobeychik G, Xu X, Yamamura T, Yang YN, Yelamos SM, Yeung M, Zacharias A, Zelkowitz M, Zettl U, Zhang M, Zhou H, Zieman U, Ziemssen T (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:1263\u20131273. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6","journal-title":"Lancet"},{"key":"2343_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdov\u00e1 EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D\u2019Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T (2021) Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 78:558\u2013567. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405","journal-title":"JAMA Neurol"},{"key":"2343_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/nejmoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401. https:\/\/doi.org\/10.1056\/nejmoa0909494","journal-title":"N Engl J Med"},{"key":"2343_CR41","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","volume":"82","author":"G Karlsson","year":"2014","unstructured":"Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, Kappos L, Collins W (2014) Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 82:674\u2013680. https:\/\/doi.org\/10.1212\/WNL.0000000000000137","journal-title":"Neurology"},{"key":"2343_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","volume":"308","author":"A Kerbrat","year":"2011","unstructured":"Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G (2011) Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting Multiple Sclerosis patients. J Neurol Sci 308:98\u2013102. https:\/\/doi.org\/10.1016\/j.jns.2011.05.043","journal-title":"J Neurol Sci"},{"key":"2343_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.msard.2017.01.001","volume":"12","author":"R Li","year":"2017","unstructured":"Li R, Sun X, Shu Y, Mao Z, Xiao L, Qiu W, Lu Z, Hu X (2017) Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: a systematic review. Mult Scler Relat Disord 12:23\u201328. https:\/\/doi.org\/10.1016\/j.msard.2017.01.001","journal-title":"Mult Scler Relat Disord"},{"key":"2343_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.804","volume":"7","author":"A Manni","year":"2017","unstructured":"Manni A, Direnzo V, Iaffaldano A, Di Lecce V, Tortorella C, Zoccolella S, Iaffaldano P, Trojano M, Paolicelli D et al (2017) Gender differences in safety issues during Fingolimod therapy: evidence from a real-life Relapsing Multiple Sclerosis cohort. Brain Behav 7:1\u20137. https:\/\/doi.org\/10.1002\/brb3.804","journal-title":"Brain Behav"},{"key":"2343_CR45","unstructured":"Massy M, Marti S, Leichtle A, Chan A, Hammer H, Thomas D, Trautmann S, Pistor M, Hoepner R Sex-specific differences in fingolimod efficacy: insights from clinical data and experimental models of multiple sclerosis. Unpublished."},{"key":"2343_CR46","doi-asserted-by":"publisher","first-page":"105134","DOI":"10.1016\/j.msard.2023.105134","volume":"81","author":"A Maunula","year":"2024","unstructured":"Maunula A, Atula S, Laakso SM, Tienari PJ (2024) Frequency and risk factors of rebound after fingolimod discontinuation: a retrospective study. Mult Scler Relat Disord 81:105134. https:\/\/doi.org\/10.1016\/j.msard.2023.105134","journal-title":"Mult Scler Relat Disord"},{"issue":"21","key":"2343_CR47","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/s0140-6736(21)00244-0","volume":"6736","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Cohen JA (2021) Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 6736(21):1184\u20131194. https:\/\/doi.org\/10.1016\/s0140-6736(21)00244-0","journal-title":"Lancet"},{"key":"2343_CR48","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.wnl.0000327609.57688.ea","volume":"71","author":"M Mehling","year":"2008","unstructured":"Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RLP, Kappos L (2008) FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 71:1261\u20131267. https:\/\/doi.org\/10.1212\/01.wnl.0000327609.57688.ea","journal-title":"Neurology"},{"key":"2343_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.257","author":"A Miravalle","year":"2011","unstructured":"Miravalle A, Jensen R, Kinkel RP (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. https:\/\/doi.org\/10.1001\/archneurol.2010.257","journal-title":"Arch Neurol"},{"key":"2343_CR50","unstructured":"MSIF TMSIF Atlas of MS: 3rd Edition (2025) https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-m. Accessed 3 Mar 2025"},{"issue":"3","key":"2343_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/metabo13030428","volume":"13","author":"F Murgia","year":"2023","unstructured":"Murgia F, Lorefice L, Noto A, Spada M, Frau J, Fenu G, Coghe G, Gagliano A, Atzori L, Cocco E (2023) Metabolomic changes in patients affected by multiple sclerosis and treated with fingolimod. Metabolites 13(3):428. https:\/\/doi.org\/10.3390\/metabo13030428","journal-title":"Metabolites"},{"key":"2343_CR52","unstructured":"National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE), Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 8 Feb 2024"},{"key":"2343_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103812","volume":"62","author":"GO Nygaard","year":"2022","unstructured":"Nygaard GO, Torgauten H, Skatteb\u00f8l L, H\u00f8gest\u00f8l EA, Sowa P, Myhr KM, Torkildsen \u00d8, Celius EG (2022) Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Mult Scler Relat Disord 62:103812. https:\/\/doi.org\/10.1016\/j.msard.2022.103812","journal-title":"Mult Scler Relat Disord"},{"key":"2343_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0165-2478(01)00339-X","volume":"81","author":"Y Okuda","year":"2002","unstructured":"Okuda Y, Okuda M, Bernard CCA (2002) Gender does not influence the susceptibility of C57BL\/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol Lett 81:25\u201329. https:\/\/doi.org\/10.1016\/S0165-2478(01)00339-X","journal-title":"Immunol Lett"},{"key":"2343_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2343_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jneuroim.2004.01.018","volume":"150","author":"TL Papenfuss","year":"2004","unstructured":"Papenfuss TL, Rogers CJ, Gienapp I, Yurrita M, McClain M, Damico N, Valo J, Song F, Whitacre CC (2004) Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains. J Neuroimmunol 150:59\u201369. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.01.018","journal-title":"J Neuroimmunol"},{"issue":"3","key":"2343_CR57","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5114\/ceji.2015.54599","volume":"40","author":"J Rudnicka","year":"2015","unstructured":"Rudnicka J, Czerwiec M, Grywalska E, Siwicka-Gieroba D, Walankiewicz M, Grafka A, Zgurski M, Surdacka A, Bartosik-Psujek H, Roli\u0144ski (2015) Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients: preliminary study. Cent Eur J Immunol 40(3):354\u2013359. https:\/\/doi.org\/10.5114\/ceji.2015.54599","journal-title":"Cent Eur J Immunol"},{"key":"2343_CR58","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.2169\/internalmedicine.0793-18","volume":"57","author":"K Sato","year":"2018","unstructured":"Sato K, Niino M, Kawashima A, Yamada M, Miyazaki Y, Fukazawa T (2018) Disease exacerbation after the cessation of fingolimod treatment in Japanese patients with multiple sclerosis. Intern Med 57:2647\u20132655. https:\/\/doi.org\/10.2169\/internalmedicine.0793-18","journal-title":"Intern Med"},{"key":"2343_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bbi.2020.04.015","volume":"88","author":"J Scarborough","year":"2020","unstructured":"Scarborough J, Mueller F, Arban R, Dorner-Ciossek C, Weber-Stadlbauer U, Rosenbrock H, Meyer U, Richetto J (2020) Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders. Brain Behav Immun 88:461\u2013470. https:\/\/doi.org\/10.1016\/j.bbi.2020.04.015","journal-title":"Brain Behav Immun"},{"key":"2343_CR60","unstructured":"U.S. Food & Drug Administration (FDA) (2012) FDA adverse event reporting system. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 8 Jul 2024"},{"key":"2343_CR61","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"MM Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BMJ, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70:1150\u20131151. https:\/\/doi.org\/10.1212\/01.wnl.0000265393.03231.e5","journal-title":"Neurology"},{"key":"2343_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20211488","volume":"219","author":"R Voskuhl","year":"2022","unstructured":"Voskuhl R, Itoh Y (2022) The X factor in neurodegeneration. J Exp Med 219:1\u201312. https:\/\/doi.org\/10.1084\/jem.20211488","journal-title":"J Exp Med"},{"key":"2343_CR63","doi-asserted-by":"publisher","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 26:1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","DOI":"10.1177\/1352458520970841"},{"key":"2343_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002685","volume":"15","author":"M Warny","year":"2018","unstructured":"Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE (2018) Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med 15:e1002685. https:\/\/doi.org\/10.1371\/journal.pmed.1002685","journal-title":"PLoS Med"},{"key":"2343_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104242","volume":"359","author":"J Wiedrick","year":"2021","unstructured":"Wiedrick J, Meza-Romero R, Gerstner G, Seifert H, Chaudhary P, Headrick A, Kent G, Maestas A, Offner H, Vandenbark AA (2021) Sex differences in EAE reveal common and distinct cellular and molecular components. Cell Immunol 359:104242. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104242","journal-title":"Cell Immunol"},{"key":"2343_CR66","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/j.jns.2015.08.1129","volume":"357","author":"UK Zettl","year":"2015","unstructured":"Zettl UK, Hecker M, Koczan D, Fitzner B, Angerer I, Friess J, Roch L, Schr\u00f6der I, Flechtner K, Thiesen HJ, Winkelmann A (2015) Profiling of lymphocyte transcriptome changes in multiple sclerosis patients treated with fingolimod. J Neurol Sci 357:e322\u2013e323. https:\/\/doi.org\/10.1016\/j.jns.2015.08.1129","journal-title":"J Neurol Sci"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02343-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02343-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02343-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:30:20Z","timestamp":1787794220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02343-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2343"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02343-6","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were approved by the local authorities (Office of Agriculture and Nature, Bern, Switzerland: BE 142\/20; external validation cohort Nieders\u00e4chsisches Landesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit (Laves), Az 33.11.42502-04-19\/3179). Ethics approval was granted by the University Medical Center G\u00f6ttingen (#19\/09\/10) for neuropathological analysis.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Massy M reports no competing interests. Marti S reports no competing interests. Kutllovci A reports no competing interests. Frahm N is an employee of the GMSR. Moreover, he is an employee of Rostock\u2019s University Medical Center and received travel funds for research meetings from Novartis. None resulted in a conflict of interest. Fneish F reports no personal financial interests to disclose other than being an employee of the GMSR. Ellenberger D reports no personal financial interests to disclose other than being an employee of the GMSR. Hammer H received speaker\/advisor honorary from Merck, Biogen, Janssen, Teva. She received research support within the last 5\u00a0years from Biogen. She received travel grants from Biogen, Roche, Janssen, Merck. Chan A received speakers\u2019\/board honoraria from Actelion (Janssen\/J&J), Alexion, Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, CSL Behring, Genzyme, and UCB, the European Union, and the Swiss National Foundation. He serves as associate editor of the European Journal of Neurology, on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research. Leichtle A reports no conflicts of interests. L\u00fchder F reports no conflicts of interests. Metz I reports personal fees from Sanofi, BiogenIdec, Bayer Healthcare, TEVA, Novartis, Roche, Neuraxpharm as well as grants from BiogenIdec and Sanofi, outside the submitted work. Pistor M received research support from the Swiss MS Society and a travel grant from Alexion. Hoepner R received speaker\/advisor honorary from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol-Myers Squibb, Teva\/Mepha and Almirall. He received research support within the last 5\u00a0years from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol-Myers Squibb. He also received research grants from the Swiss MS Society, the SITEM Insel Support Fund and is a member of the Advisory Board of the Swiss and International MS Society. He also serves as deputy editor in chief for Journal of Central Nervous System disease and is part of the ECTRIMS Young Investigator Committee.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"179"}}